חיסון נגד כלמידיה עבר את מבחני הבטיחות הראשוניים

The study, published in The Lancet Infectious Diseases journal, found that in a clinical trial of 35 healthy women, a vaccine shows early signs of effectiveness against genital כלמידיה.

Chlamydia is a זיהום המועבר במגע מיני (STI) which is most common in under-25s, affecting between 3-7% of sexually active young people in the UK. The majority of people experience no symptoms but complications which can develop include עקרות ו מחלת דלקת אגן.

In 2018 there were 218,095 diagnosed cases of chlamydia across the UK population, equating to nearly half of all new STI diagnoses. In the last five years, uptake of chlamydia screening has dropped by 22% but the proportion testing positive has increased.

Thus far, public health campaigns and treatment programmes have been largely ineffective in curbing the epidemic. Tests and antibiotic treatment are successful in detecting and treating chlamydia, but low public engagement and availability have prevented them from being effective.

A vaccination programme to prevent chlamydia occurring in the first place is thought to be a much better way of preventing its spread and complications. No previous chlamydia vaccines have reached human clinical trials.

Women are particularly at risk of complications from chlamydia. One in six women who have chlamydia develop pelvic inflammatory disease when the infection travels up from the cervix. This can cause chronic pelvic pain, infertility and הריון חוץ רחמי, particularly in areas of the world where there is limited access to treatment and screening. Chlamydia is also strongly associated with a greater risk of having other STIs, especially HIV ו זיבה. Chlamydia during pregnancy increases the risk of negative outcomes like הפלה, stillbirth and preterm birth.

"Given the impact of the chlamydia epidemic on women's health, reproductive health, infant health through vertical transmission, and increased susceptibility to other sexually transmitted diseases, a global unmet medical need exists for a vaccine against genital chlamydia," explains author of the study, Professor Peter Andersen, from Statens Serum Institut, Denmark.

The 35 women included in the trial did not have chlamydia and were split into three groups, two with a different version of the vaccine (to see which was more effective) and one placebo group. In total, 32 participants received all five vaccinations in the course.

100% of those who received the vaccine had an immune response, whereas none of those in the placebo group did. One of the vaccines, called CTH522:CAF01, consistently performed better than the other and produced 5.6 times more antibodies. It is suggested that this vaccine be used for further clinical trials.

No serious side effects of the vaccination were reported although all of those who received the vaccine had mild skin reactions at the site of injection and some experienced mild pain or tenderness for a couple of days.

Despite showing an effective immune response, it is not yet known whether this translates into immunity to protect against chlamydia.

First author of the study, Helene Juel of the Statens Serum Institut, Denmark, reflected on the success of the first clinical trial. "Studies of antibodies in mice have found that antibodies in the vagina are the first line of defence against chlamydia infection, which suggests they are key to how effective the new vaccine may be."

"A vaccine for prevention of C. trachomatis infection [chlamydia] would have enormous public health and economic impact. Although clinical vaccine testing for chlamydia is in its infancy, this trial suggests optimism for the future," says Professor Toni Darville from University of South Carolina.

This study was published in The Lancet Infectious Diseases.